Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.

Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, kConFab, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG.

Hum Mutat. 2012 Jan;33(1):95-9. doi: 10.1002/humu.21625. Epub 2011 Nov 4.

PMID:
21990120
2.

Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.

Vuorela M, Pylkäs K, Hartikainen JM, Sundfeldt K, Lindblom A, von Wachenfeldt Wäppling A, Haanpää M, Puistola U, Rosengren A, Anttila M, Kosma VM, Mannermaa A, Winqvist R.

Breast Cancer Res Treat. 2011 Dec;130(3):1003-10. doi: 10.1007/s10549-011-1677-x. Epub 2011 Jul 13.

PMID:
21750962
3.

Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families.

Osorio A, Endt D, Fernández F, Eirich K, de la Hoya M, Schmutzler R, Caldés T, Meindl A, Schindler D, Benitez J.

Hum Mol Genet. 2012 Jul 1;21(13):2889-98. doi: 10.1093/hmg/dds115. Epub 2012 Mar 26.

PMID:
22451500
4.

Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.

Zheng Y, Zhang J, Hope K, Niu Q, Huo D, Olopade OI.

Breast Cancer Res Treat. 2010 Dec;124(3):857-61. doi: 10.1007/s10549-010-1095-5. Epub 2010 Aug 10.

PMID:
20697805
5.

RAD51C is a susceptibility gene for ovarian cancer.

Pelttari LM, Heikkinen T, Thompson D, Kallioniemi A, Schleutker J, Holli K, Blomqvist C, Aittomäki K, Bützow R, Nevanlinna H.

Hum Mol Genet. 2011 Aug 15;20(16):3278-88. doi: 10.1093/hmg/ddr229. Epub 2011 May 25.

PMID:
21616938
6.

Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.

Rashid MU, Muhammad N, Faisal S, Amin A, Hamann U.

Breast Cancer Res Treat. 2014 Jun;145(3):775-84. doi: 10.1007/s10549-014-2972-0. Epub 2014 May 7.

PMID:
24800917
7.

A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families.

Romero A, Pérez-Segura P, Tosar A, García-Saenz JA, Díaz-Rubio E, Caldés T, de la Hoya M.

Breast Cancer Res Treat. 2011 Oct;129(3):939-46. doi: 10.1007/s10549-011-1543-x. Epub 2011 May 3.

PMID:
21537932
8.

Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing.

De Leeneer K, Van Bockstal M, De Brouwer S, Swietek N, Schietecatte P, Sabbaghian N, Van den Ende J, Willocx S, Storm K, Blaumeiser B, Van Asperen CJ, Wijnen JT, Leunen K, Legius E, Michils G, Matthijs G, Blok MJ, Gomez-Garcia E, De Paepe A, Tischkowitz M, Poppe B, Claes K.

Breast Cancer Res Treat. 2012 May;133(1):393-8. doi: 10.1007/s10549-012-1998-4. Epub 2012 Feb 28.

PMID:
22370629
9.

Germline mutations in RAD51C in Jewish high cancer risk families.

Kushnir A, Laitman Y, Shimon SP, Berger R, Friedman E.

Breast Cancer Res Treat. 2012 Dec;136(3):869-74. doi: 10.1007/s10549-012-2317-9. Epub 2012 Nov 2.

PMID:
23117857
10.

Germline mutation in the RAD51B gene confers predisposition to breast cancer.

Golmard L, Caux-Moncoutier V, Davy G, Al Ageeli E, Poirot B, Tirapo C, Michaux D, Barbaroux C, d'Enghien CD, Nicolas A, Castéra L, Sastre-Garau X, Stern MH, Houdayer C, Stoppa-Lyonnet D.

BMC Cancer. 2013 Oct 19;13:484. doi: 10.1186/1471-2407-13-484.

11.

RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.

Blanco A, Gutiérrez-Enríquez S, Santamariña M, Montalban G, Bonache S, Balmaña J, Carracedo A, Diez O, Vega A.

Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.

PMID:
25086635
12.

Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden.

Johannsson O, Ostermeyer EA, Håkansson S, Friedman LS, Johansson U, Sellberg G, Brøndum-Nielsen K, Sele V, Olsson H, King MC, Borg A.

Am J Hum Genet. 1996 Mar;58(3):441-50.

13.

RAD51C germline mutations in breast and ovarian cancer patients.

Akbari MR, Tonin P, Foulkes WD, Ghadirian P, Tischkowitz M, Narod SA.

Breast Cancer Res. 2010;12(4):404. doi: 10.1186/bcr2619. Epub 2010 Aug 19. No abstract available.

14.

Genetic testing for RAD51C mutations: in the clinic and community.

Sopik V, Akbari MR, Narod SA.

Clin Genet. 2015 Oct;88(4):303-12. doi: 10.1111/cge.12548. Epub 2015 Jan 7. Review.

PMID:
25470109
15.

Frequency of the ATM IVS10-6T-->G variant in Australian multiple-case breast cancer families.

Lindeman GJ, Hiew M, Visvader JE, Leary J, Field M, Gaff CL, Gardner RJ, Trainor K, Cheetham G, Suthers G, Kirk J.

Breast Cancer Res. 2004;6(4):R401-7. Epub 2004 Jun 2.

16.

Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.

Jønson L, Ahlborn LB, Steffensen AY, Djursby M, Ejlertsen B, Timshel S, Nielsen FC, Gerdes AM, Hansen TV.

Breast Cancer Res Treat. 2016 Jan;155(2):215-22. doi: 10.1007/s10549-015-3674-y. Epub 2016 Jan 6.

PMID:
26740214
17.

Novel germline mutations in BRCA2 gene among 96 hereditary breast and breast-ovarian cancer families from Kerala, South India.

Syamala V, Sreeja L, Syamala VS, Vinodkumar B, Raveendran PB, Sreedharan H, Kuttappan R, Balakrishnan L, Ankathil R.

J Cancer Res Clin Oncol. 2007 Nov;133(11):867-74. Epub 2007 May 15.

PMID:
17503080
18.

RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.

Krivokuca A, Yanowski K, Rakobradovic J, Benitez J, Brankovic-Magic M.

Cancer Biomark. 2015;15(6):775-81. doi: 10.3233/CBM-150519.

PMID:
26406419
19.

Germline RAD51C mutations in ovarian cancer susceptibility.

Coulet F, Fajac A, Colas C, Eyries M, Dion-Minière A, Rouzier R, Uzan S, Lefranc JP, Carbonnel M, Cornelis F, Cortez A, Soubrier F.

Clin Genet. 2013 Apr;83(4):332-6. doi: 10.1111/j.1399-0004.2012.01917.x. Epub 2012 Jul 23.

PMID:
22725699
20.

Mutation screening of RAD51C in high-risk breast and ovarian cancer families.

Lu W, Wang X, Lin H, Lindor NM, Couch FJ.

Fam Cancer. 2012 Sep;11(3):381-5. doi: 10.1007/s10689-012-9523-9.

Supplemental Content

Support Center